Joan Shen ends the year by say­ing good­bye to I-Mab; CRISPR Ther­a­peu­tics puts coal in R&D chief's stock­ing

Deck the halls with more ap­point­ments in the last Peer Re­view for 2021. Thanks for read­ing every week!

→ When the cal­en­dar flips to 2022, Joan Shen is out at I-Mab “to pur­sue oth­er in­ter­ests,” leav­ing founder and chair­man Jing­wu Zang to suc­ceed her as act­ing CEO in a bit of a sur­prise. Un­der Shen’s lead­er­ship, I-Mab formed a CD47 al­liance with Ab­b­Vie in Sep­tem­ber 2020 with lem­zopar­limab as the cen­ter­piece, and a year lat­er our Am­ber Tong de­tailed I-Mab’s as­pi­ra­tions for oth­er com­pa­ra­ble part­ner­ships, no­tably for de­vel­op­ment of the CD73 an­ti­body uliledlimab. Shen was one of our 20 Women in Bio­phar­ma R&D hon­orees this month.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.